Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia

NCT01363349 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

269

Enrollment

INDUSTRY

Sponsor class

Stopped pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020 indicate that the trial would not meet the pre-specified primary efficacy endpoint.

Conditions

Schizophrenia
Cognitive Effect on Schizophrenic Patients

Interventions

DRUG: CYP-1020
DRUG: Risperidone

Sponsor

BioLineRx, Ltd.